What We Do

Through the integration of plan-specific drug claims data with our proprietary analytics systems and reporting applications, our team of experts answer questions, provide information and seek solutions for our clients related to:

Optimizing Plan Performance

How can we contain our drug plan costs without taking anything away from the plan? How do we manage costs without adversely affecting the health or productivity of our plan members? How can we get more for less?
What is the current impact of expensive specialty drugs (e.g. biologicals) within our plan experience? How can we afford coverage for these products in the future?
What value does our current stop-loss provision have as a risk management strategy?
Is there any misuse or abuse of the plan occurring among plan members (e.g. excessive narcotic use)? What impact has our new therapeutic limits program had in addressing this issue?

Quantifying the Impact of Plan Designs

How well is our current plan design containing costs?
What impact will an alternative plan design and/or formulary have on our plan? On our plan members?
Has there been any change in plan member behaviour following the implementation of our new plan design? Is the new design having any beneficial impact?

Assessing Risk

Is there really a liability in moving to a pay-direct drug (PDD) plan? What is the actual impact of the “shoebox effect” within our reimbursement plan? To what extent is this potential liability offset by opportunities for savings in a PDD plan structure?
What is our future risk for claims for expensive specialty drugs and medications used to treat common age-related chronic conditions? How will this impact our claims costs moving forward?
What is our plan’s post-retirement liability trend based on our own unique experience and plan demographic? How does this compare with actuarial estimates?

Assessing Service Provider Options

Which preferred pharmacy provider(s) is/are the best fit and provide the most value for our plan and our plan members? How can our plan design be modified to support preferred offerings?
What health service providers and wellness vendors have programs that best meet our population health profile?

Forecasting Future Costs

What will our plan costs be moving forward if we decide not to make any plan design changes? What do we need to budget for?
What do we need to know about specific cost challenges looming in the future in order to prepare for collective bargaining or strategic planning meetings?
What impact will legislated provincial pricing changes and the genericization of key brand products have on our current plan costs? Will they affect our planning for the future?

Profiling Population Health

What key disease states are driving our plan utilization and are the most prevalent among all of our plan members? Within the workplace itself?
What is the overall burden of illness for our drug and disability experiences combined (i.e. breaking down the silos)? How do we ensure our drug plan benefit is positively impacting our absence and disability experience?
What disease states have the most significant co-morbid chronic conditions in the workplace? How does this impact the health and wellness programs being considered?

Measuring Return on Investment

Is our investment in plan design changes and/or vendor partnerships producing a return?
To what extent are high-priced specialty drugs keeping our employees at work? What is the cost offset of specialty drug spending through reduced absenteeism and disability expenditures?
What is the business case for targeting a specific disease state like depression in the workplace?

Drug Product Data Subscriptions

Cubic Health maintains the most comprehensive collection of drug product information and drug classifications including the SFC Therapeutic Classification System™ in Canada within in our Cubic Health Canadian Drug Database™.
This information is vital to groups who need accurate, real-time information, and is available on a subscription basis to TPAs, Claims Processors, Carriers and other industry stakeholders